source
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and moreSanofi asked the FDA to pull teplizumab out of a speedy review voucher program after a political appointee disagreed with staff over its approvalSTAT · 4mo ago↗ source
- STAT+: FDA revisits a rare cancer treatment it rejected a few months agoSecret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The ReadoutSTAT · 4mo ago↗ source
- Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.onclive · 4mo ago